Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
By W. Wang, Eq Wang, J. Balthasar. Clinical pharmacology and therapy, 2008
966 citations recorded by the source corpus.
Subfields: Genetics, Molecular Biology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/22d075c590102a549f4c35c36e73854320feb04c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Jan-Frederik Schlender
- Edward Posvar
- Donato Teutonico
- G. Jang
- Christoph Niederalt
- L. Kuepfer
- S. Willmann
- B. Stouch
Citations in the corpus
- Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model (2016, background): “Passive and active processes for large molecules Therapeutic proteins are an increasingly important class of drugs.(70) PK/PD modeling of therapeutic proteins differs from those of small-molecule drugs, mainly due to the differences in size.”
- Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody (2011, background): “dose groups.((24)) Peak AMG 785 serum concentrations occurred within the first week following s.”